Viewing Study NCT05170256


Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2025-12-25 @ 8:55 PM
Study NCT ID: NCT05170256
Status: UNKNOWN
Last Update Posted: 2022-08-12
First Post: 2021-11-24
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients
Sponsor: Morten Mau-Sørensen
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module